Polycystic Ovary Syndrome Renamed to Polyendocrine Metabolic Ovarian Syndrome in Landmark Consensus

Polycystic ovary syndrome (PCOS), a hormonal disorder affecting approximately 10% of reproductive-aged women globally, is being renamed polyendocrine metabolic ovarian syndrome (PMOS) following an international expert consensus published in The Lancet in May 2024. The change aims to better reflect the condition’s complex metabolic and endocrine components, according to the statement co-authored by the Endocrine Society and the European Society of Human Reproduction and Embryology.

What is PMOS, and Why the Name Change?

The renaming stems from growing recognition that PCOS extends beyond ovarian cysts to involve insulin resistance, metabolic dysfunction, and hormonal imbalances. The updated term, PMOS, emphasizes the syndrome’s systemic nature, which includes risks for type 2 diabetes, cardiovascular disease, and infertility. “The previous name was overly simplistic and did not capture the full scope of the condition,” said Dr. Sarah Berga, a reproductive endocrinologist and co-author of the consensus statement. “This shift will improve diagnosis and treatment approaches.”

The consensus, which included input from over 50 researchers and clinicians, highlights that PMOS affects 5–10% of women of childbearing age, with symptoms often persisting into menopause. The new nomenclature aligns with broader efforts to standardize terminology for complex metabolic disorders, as noted in a CDC report on hormonal health.

How Will This Affect Patients and Researchers?

The reclassification is expected to influence clinical guidelines, insurance coverage, and research priorities. For example, studies previously focused on ovarian morphology may now prioritize metabolic markers like insulin levels and waist circumference. “This change will encourage a more holistic view of patient care,” said Dr. Ravi Retnakaran, an endocrinologist at the University of Toronto. “We’re moving from a narrow, organ-based perspective to a systems-based one.”

Researchers also anticipate shifts in funding allocations. The National Institutes of Health (NIH) has already announced plans to expand its PMOS-related grants, citing the need for “longitudinal studies on metabolic outcomes,” according to a NIH press release. However, some experts caution that renaming alone may not address gaps in care. “The real challenge is ensuring that healthcare providers adopt these updates in practice,” said Dr. Andrea Dunaif, a pioneer in PCOS research.

What Are the Broader Implications for Women’s Health?

The name change reflects a broader trend in medicine to move beyond organ-centric diagnoses. Similar shifts have occurred with conditions like “metabolic syndrome,” which now encompasses multiple risk factors. For women, the reclassification could lead to earlier interventions for related conditions. For instance, a 2023 New England Journal of Medicine study found that women with PMOS were 3.2 times more likely to develop type 2 diabetes than those without the condition.

Advocacy groups, including the PCOS Foundation, have welcomed the update but stressed the need for public education. “Many women still believe PCOS is solely about irregular periods or acne,” said CEO Lisa Hark. “PMOS provides a more accurate framework for understanding the long-term risks.”

What’s Next for PMOS Research and Treatment?

Experts predict a surge in studies exploring the interplay between genetics, environment, and metabolism in PMOS. The consensus statement also calls for standardized diagnostic criteria, which vary widely across countries. “We need a unified approach to ensure equitable care,” said Dr. Mihara Tamaru, a Japanese endocrinologist involved in the initiative.

Treatment strategies may also evolve. While lifestyle modifications remain the cornerstone of care, new therapies targeting insulin sensitivity and inflammation are in development. A phase III trial of a novel GLP-1 receptor agonist for PMOS is set to begin in 2025, according to FDA records.

The shift to PMOS marks a pivotal moment in understanding a condition that has long been underdiagnosed and misunderstood. As research advances, the focus will increasingly center on managing its metabolic consequences—a critical step in improving outcomes for millions of women worldwide.